OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
ModifiedBlue Cross Blue Shield - TexasPolicy N/A
Prior Authorization and Medical Necessity Updates for Advanced Imaging, Molecular Genetic, and Related Services
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Texas policy alerts
Know when Blue Cross Blue Shield - Texas releases new policies or updates existing guidance.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
Lists CPT/HCPCS/temporary codes for advanced imaging, molecular genetic, and selected procedure categories that may require prior authorization, describes managed-by assignments (Carelon, Alacura), and notes addition of site-of-care to medical necessity criteria effective 01/01/2025.
Policy Summary
PayerBlue Cross Blue Shield - Texas
PolicyPrior Authorization and Medical Necessity Updates for Advanced Imaging, Molecular Genetic, and Related Services
Policy CodePolicy N/A
Change TypeAdded site-of-care to medical necessitymultiple molecular/U-code assignments and vendor changes
Effective Date01/01/2025
Next Review DateN/A
Key ActionSubmit prior authorization requests for listed codes to the designated manager (Carelon or Alacura) and include site-of-care information per updated medical necessity requirements.
Addition of site of care to the medical necessity criteria for numerous advanced imaging CPT codes effective 01/01/2025.
Update Category name from "Non-Emergent Air Ambulance" to "Medical Transportation" effective 01/01/2025 and changed services management from BCBSTX to Alacura for affected codes.
Multiple molecular genetic and U‑codes (e.g., 0575U, 0576U, 0578U, 0582U, 0583U, 0585U, 0586U, 0592U, 0597U) are assigned to "Medical Transportation" category and services management changed to Carelon/Alacura with effective add-dates (01/01/2025 and 01/01/2026 or 04/01/2025 for specific codes).
Multiple new molecular genetic laboratory test codes (04xxxU–05xxxU and specific S/G/G codes) were added with Carelon listed as the prior authorization administrator and various effective dates (many 07/01/2025, 10/01/2025, or 04/01/2025).
Several oncology and obstetrics noninvasive prenatal test codes (e.g., 0485U, 0486U, 0487U, 0489U, 0493U–0499U) added and marked Carelon.
Listed procedures may require prior authorization and have updated medical necessity criteria
Prior authorization list membership: Procedure code is on the payer's prior authorization list
Presence on list does not guarantee coverage; member benefits determine final coverage
Managed-by assignment: Many codes are managed by Carelon (or other vendors as specified) for prior authorization review
See individual code entries for managed-by vendor
Site-of-care update: Effective 01/01/2025, 'site of care' was added to medical necessity criteria for many imaging codes
Applies to codes indicated in the list
General prior authorization and medical necessity requirement (excerpt)
Covered when prior authorization is obtained and medical necessity criteria (including site-of-care) are met
Authorization and medical necessity: Prior authorization must be obtained through Carelon for listed CPT codes and medical necessity will be evaluated including site-of-care information effective 01/01/2025.
Prior authorization required
Covered when prior authorization is obtained for the listed CPT codes from the designated reviewer
Authorization requirement: Prior authorization must be obtained from Carelon for any of the listed CPT codes before service
Applies to the CPT codes enumerated in this section; submit to Carelon.
Prior authorization requirement
Listed procedures require prior authorization
Prior authorization required: Prior authorization must be obtained for the specific CPT/HCPCS/L-codes and Category III codes listed in this section before performing or billing the service
Many entries indicate the authorization processor (Carelon or BCBSTX).
Prior authorization requirement
Covered when prior authorization is obtained for listed procedures/codes and routed to the assigned services manager where indicated.
Prior authorization requirement: Prior authorization must be obtained for the specific codes listed in this section; some codes have assigned vendor (Alacura or Carelon) and effective dates that govern authorization routing.
No additional clinical criteria provided in this excerpt; provider must follow payer/vendor submission instructions.
Prior authorization required
Prior authorization required
Prior authorization requirement: Prior authorization is required for the listed CPT codes (81345–81364, 81400–81406) and associated molecular genetic/molecular pathology tests
Carelon is listed as the authorization vendor in multiple entries
Panel-specific coverage criteria
Coverage applies when panel-specific gene content and indication requirements are met
Panel composition and indication: The genomic sequence or duplication/deletion panel must include sequencing (and where required, duplication/deletion or RNA analysis) of the minimum set of genes specified for that indication (examples: aortic dysfunction panel must include at least 9 genes; hearing loss panels must include at least 60 genes; mitochondrial gene panels must include at least 100 genes).see code-specific requirements
Each CPT code in the list includes its own required gene list or minimum gene count.
Coverage contingent on prior authorization
Covered when prior authorization is obtained for the listed tests
Authorization requirement: Tests listed in this section require prior authorization through the designated manager (Carelon) as identified next to each code
Includes a variety of molecular/genetic CPT and proprietary codes
Prior Authorization Requirement: Prior authorization must be obtained through Carelon for the listed molecular genetic (temporary/PLA) procedure codes before claim submission.
Each code entry includes 'Carelon' indicating the prior authorization vendor.
Authorization requirement
Covered when prior authorized through Carelon per payer policy
Prior authorization requirement: Order must be prior authorized through Carelon for codes listed in this section.
No additional clinical necessity criteria provided in these chunks.
Prior authorization requirement for listed molecular/genetic tests
Covered when prior authorization is obtained for the listed codes and indications as specified
PA required: Prior authorization through Carelon is required for the listed molecular genetic testing codes before coverage will be considered.
Effective dates provided for many codes; include code-specific effective date when requesting PA.
Authorization requirement
Covered when prior authorization is obtained
Prior Authorization: Procedure code is one of the listed musculoskeletal or spine CPT codes AND prior authorization is obtained through Carelon
Prior auth routing specified to Carelon in document excerpts
The presence of codes on this prior authorization list does not by itself guarantee coverage under a member's benefits contract. Member benefits vary; providers should consult the member's benefit booklet or contact customer service to confirm whether a specific service is covered before scheduling or performing the procedure. Codes on this list indicate that prior authorization may be required beginning 01/01/2025 unless otherwise noted, but final coverage depends on the individual member contract.
This excerpt does not enumerate explicit clinical denial conditions, but it makes clear that failure to obtain required prior authorization or to supply requested information (including the newly required site-of-care detail effective 01/01/2025) may result in denial of coverage for services listed under the advanced imaging/radiology codes. Providers should submit prior authorization requests to the designated administrator (Carelon when indicated) and ensure that all requested documentation is included.
No explicit exclusion conditions for the listed codes are provided in this excerpt. The document enumerates codes that require prior authorization or routing to a specific services manager but does not list service-level exclusions within these chunks; absence of an exclusion here does not imply coverage — verify member benefits and any code-specific guidance in the full policy.
This excerpt does not state any specific additional clinical coverage conditions beyond the requirement for prior authorization. Where molecular genetic CPT codes are listed, the document identifies authorization routing (e.g., Carelon) and, for some codes, effective or retirement dates; no further explicit exclusions are described in these segments.
There are no explicit clinical coverage criteria or exclusions given in these chunks; instead, the molecular genetic CPT codes are listed with the authorization manager (Carelon) and — for many entries — panel composition or gene-count expectations. Coverage consideration requires that prior authorization be obtained per the listing and that any code-specific panel requirements (when noted) be met.
Certain molecular genetic codes in this excerpt are annotated with retirement actions. For example, entries for codes such as 81433 and 81436 (and others noted in the same segment) include a retirement effective date of 04/01/2025. Providers should confirm code validity and effective/retirement dates when preparing prior authorization requests and submitting claims.
This section of the document does not list explicit exclusions; it primarily identifies molecular/genetic test codes that require prior authorization through the named administrator (typically Carelon) and, where applicable, provides effective dates or panel composition requirements. Absence of exclusions in these chunks means providers must rely on the code-specific descriptors and the member contract to determine coverage and necessity.
This list includes CPT, HCPCS, and proprietary codes for which prior authorization may be required effective January 1, 2025 (unless an alternate effective/retirement date is shown). Presence of a code on this prior authorization list does not guarantee coverage under the member's benefits contract — verify the member's benefit booklet or contact Customer Service. Failure to obtain required prior authorization may result in claim denial.
Prior authorization may be required for listed codes — the codes shown throughout the document are included on the payer's prior authorization list and may require prior authorization.
Prior authorization required — designated reviewer: Carelon — Many advanced imaging, molecular/genetic, musculoskeletal/spine, and other procedure codes listed identify Carelon as the prior authorization reviewer/authorization manager. Providers must submit requests to Carelon for those codes.
Codes requiring prior authorization (partial) — This section contains partial listings (examples) of CPT/HCPCS/U-codes and proprietary codes that require prior authorization; the full searchable list should be used to confirm all affected codes.
Prior authorization requirement for listed test codes — Molecular genetic laboratory tests and many genomic panels listed (CPT 812xx, 813xx, 814xx; U-/004xx/00xxx series) require prior authorization; each entry includes a code and a short descriptor (specialty/indication, specimen type, and testing method) to support the request.
Prior authorization required for listed CPT codes — Many procedure and advanced imaging CPT codes (including but not limited to CT, MRI, PET, angiography, and specialized nuclear medicine procedures) require prior authorization.
Prior Authorization Scope
Note
Note
Note
Note
Note
Note
Note
Contrast and Study Variant Rules
Note
Note
Note
Note
Background and Scope
This background material explains that the file provides administrative and utilization management context for imaging and related services, including the prior authorization process and managed-by assignments. It notes the policy update effective 01/01/2025site of care to medical necessity evaluation for many advanced imaging CPT codes and repeatedly identifies Carelon (and where applicable Alacura/BCBSTX) as the authorization manager for listed codes. The document excerpt does not include detailed clinical indications within these chunks; its primary purpose here is to list codes and the operational PA routing and requirements.
Definitions and Acronyms
Indicator on member ID cards for Fully Insured Members effective 01/01/2026
ID card indicator (TDI)TDI will be indicated on Fully Insured members' ID cards effective 01/01/2026
PurposeNotation alerts providers and members to the insurer designation on ID cards for fully insured members
ReferenceSee payer communication and ID card guidance (updated October 2025)
PET/CT
PET/CT definitionPositron emission tomography with concurrently acquired CT for attenuation correction and anatomical localization as described for codes 78814–78816 and 78830–78832
Example codesCodes referenced include 78814, 78815, 78816 (PET with CT transmission) and 78830 (SPECT with CT) in the PET/CT context
Policy Update Changes
2025-01-01policy_update
Effective 01/01/2025, site-of-care was added to medical necessity criteria for numerous advanced imaging CPT codes and prior authorization routing/managed-by assignments were updated (Carelon/Alacura) including renaming the category 'Non-Emergent Air Ambulance' to 'Medical Transportation'.
2025-04-01code_effective_date
Several molecular genetic CPT codes (e.g., 81195 and others noted in the list) were assigned specific effective or retirement dates effective 04/01/2025 as indicated in code entries.
2025-07-01policy_update
Policy Summary
PayerBlue Cross Blue Shield - Texas
PolicyPrior Authorization and Medical Necessity Updates for Advanced Imaging, Molecular Genetic, and Related Services
Policy CodePolicy N/A
Change TypeAdded site-of-care to medical necessitymultiple molecular/U-code assignments and vendor changes
Effective Date01/01/2025
Next Review DateN/A
Key ActionSubmit prior authorization requests for listed codes to the designated manager (Carelon or Alacura) and include site-of-care information per updated medical necessity requirements.
Claims for the listed procedure codes may be denied without prior authorization — Services included in this document (Medical Surgical Procedures Requiring Prior Authorization) may be denied if prior authorization is not obtained when required.
Claims for the listed molecular genetic lab testing CPT codes may be denied without prior authorization — The molecular/genetic CPT, PLA, U- and J-codes listed are subject to prior authorization review by Carelon and may be denied if authorization is not obtained.
Tests listed in this section are identified as "Medical Surgical Procedures Requiring Prior Authorization" and therefore will be subject to utilization management review.
Submit prior authorization requests to designated reviewer — For codes managed by Carelon, providers must submit prior authorization requests to Carelon; for codes managed by BCBSTX or Alacura the document indicates the routing vendor. Site-of-care information and supporting documentation (test description, specimen type, clinical indication, panel composition when applicable) are often required.
Prior authorization routing vendor is specified for many codes (Carelon or BCBSTX or Alacura) — Providers must reference the list to determine the correct services management vendor for submission.
Submission routing and vendor — Prior authorization requests for advanced imaging and molecular/genetic tests are generally routed to Carelon as the vendor; some services (e.g., certain infusion or transportation codes) may be routed to Alacura or handled by BCBSTX as indicated in the list.
Authorization manager and required submission — Each code entry includes the designated authorization manager (e.g., Carelon, BCBSTX, Alacura); providers must submit to the named administrator and include the code, short test/procedure descriptor, and any required clinical documentation.
Provider must submit prior authorization to the listed administrator — For each molecular/genetic or procedural test identified, the provider must submit the PA request to the named reviewer (Carelon in most molecular cases) including the code and supporting documentation.
Each listed procedure is identified by its code and short descriptor — Use the code and descriptor provided in the list when preparing prior authorization requests to ensure accurate routing and review.
Test code and description required — When submitting PA for molecular/genetic tests, include the test code (CPT/PLA/U/J), brief test description (genes/panel and methodology), specimen type, and indication as shown in the list.
Authorization routing — Verify the services management vendor in the code listing (Carelon, BCBSTX, Alacura) before submission; routing affects where and how the PA is submitted.
Some specific codes include retirement or alternate effective dates — Several U-/0078U/0380U/etc. entries include retire or add effective dates (e.g., 0078U retire effective 07/01/2025; 0380U retire effective 04/01/2025; others add effective 07/01/2025 or 01/01/2026). Check the 'Updates' column for date-specific handling.
Note
Note
Note
Note
Note
Authorization vendorCarelon is listed as the prior authorization manager for PET/CT codes in the document
Transthoracic echocardiography
Transthoracic echocardiography codesCPT 93303, 93304, 93306, 93307 — transthoracic echocardiography for congenital anomalies and standard 2D/Doppler studies listed as requiring prior authorization
ScopeIncludes complete and limited/follow-up transthoracic studies and related stress/contrast variants where coded
Authorization vendorCarelon is identified as the prior authorization reviewer for these echocardiography entries
0648T / 0649T
0648T / 0649T descriptionQuantitative magnetic resonance for analysis of tissue composition (e.g., fat/iron/water content) including multiparametric acquisition and reporting
CategoryCategory III / advanced MRI quantitative procedures are listed and require prior authorization
Authorization vendorEntries for 0648T/0649T reference Carelon for prior authorization routing
78831 / 78832
78831 / 78832 descriptorRadiopharmaceutical localization including tomographic (SPECT) studies with or without concurrently acquired CT for anatomical localization; minimum 2 areas or separate acquisitions
SPECT variants78831 = SPECT minimum 2 areas or separate acquisitions; 78832 = SPECT with concurrently acquired CT, same minimum area requirements
Authorization vendorCarelon is listed as the prior authorization reviewer for these codes
Carelon
Carelon — authorization managerCarelon is the named authorization/management entity for many molecular genetic test entries listed in the document
Provider actionProviders must submit prior authorization requests to the manager identified (Carelon) for the specified molecular genetic CPT/PLA/U codes
Effective datesMany code entries include effective or add dates that affect authorization routing; check individual code entries
Molecular pathology procedure levels
Molecular pathology levelsLevels 1–6 represent increasing complexity: Level 1 (81400) single variant; Level 2 (81401) 2–10 SNPs or methylation; Level 3 (81402) >10 SNPs or complex rearrangements; Level 4 (81403) single exon or >10 amplicons; Level 5 (81404) analysis of 2–5 exons; Level 6 (81405) analysis of 6–10 exons
Use in PAPrior authorization listings reference these levels when indicating test complexity and requirements
Genomic sequence analysis panel
Genomic sequence analysis panel definitionA multi-gene testing panel that performs sequencing (and where specified, duplication/deletion analysis or RNA analysis) for a defined set of genes for a given hereditary or neoplastic indication; many codes require panels to include sequencing of a minimum number of named genes
Panel requirementsIndividual CPT/U codes specify required gene lists, minimum gene counts, and whether duplication/deletion or RNA analysis is required
Authorization implicationsProviders must document panel composition and indication when requesting prior authorization
Whole mitochondrial genome
Whole mitochondrial genome testSequence analysis of the entire mitochondrial genome with heteroplasmy detection for mitochondrial disorders (e.g., MELAS, MERRF, NARP, LHON)
Relevant CPTCPT 81460 (whole mitochondrial genome) and related U/PLA codes reference heteroplasmy detection and whole-mitochondrial sequencing
Authorization vendorCarelon is listed as prior authorization manager for mitochondrial genome testing entries
Cell-free nucleic acid (plasma)
cfDNA / ctDNA definitionPlasma-based interrogation of tumor-derived cell-free DNA/RNA for sequence variants, copy number variants and rearrangements
Relevant CPTsCodes such as 81462–81464 reference cell-free nucleic acid (plasma) analyses for solid organ neoplasm panels
Use caseUsed in oncology genomic panels and cfDNA-based assays requiring prior authorization
Temporary/PLA (U) codesProcedure descriptors in this section are temporary or PLA HCPCS-like codes (e.g., 0055U, 0078U) representing molecular/genetic tests such as targeted gene panels, cell-free assays, and expression profiling
Coverage implicationThese temporary/PLA codes are listed as requiring prior authorization through the designated manager (Carelon) where indicated
ExamplesThe document lists many U/PLA codes across oncology, transplant, and hereditary testing categories — review specific code entries for gene counts and methods
Molecular genetic lab testing
Molecular genetic lab testing (general)Molecular genetic laboratory testing entries include detailed test descriptors, gene panels, and methods and are listed as requiring prior authorization
Provider requirementProviders must submit the specific test code and descriptor when requesting prior authorization
Authorization managerCarelon is frequently listed as the prior authorization administrator for these tests
Proprietary laboratory test billing codes (U-code)
U-code definitionProprietary laboratory test billing codes (CPT Category II/III or proprietary laboratory codes) used to identify specific molecular genetic services (U/J/004xx series)
ExamplesMultiple U/J codes (e.g., 0336U, 0340U, 0473U, 0543U) specify panel size, method (NGS, digital PCR), and indications in their descriptors
Authorization implicationThese proprietary U/J codes require prior authorization and list Carelon as the authorization manager for many entries
cell-free DNA (cfDNA) / circulating tumor DNA (ctDNA)
cfDNA / ctDNA termcfDNA / circulating tumor DNA (ctDNA) assays are described for oncology and transplant monitoring (e.g., donor-derived cfDNA quantification), often requiring NGS or digital PCR methods
Representative codesExamples include 0543U and 0544U for donor-derived cfDNA quantification and multiple 0485U–0487U/0473U entries for tumor cfDNA panels
Authorization vendorCarelon is listed as the prior authorization manager for these cfDNA/ctDNA assays
Next-generation sequencing (NGS)
Next-generation sequencing (NGS)NGS refers to high-throughput sequencing methods used to detect SNVs, indels, CNVs, fusions, methylation patterns, and tumor mutation burden as described in multiple code entries
Use in codesNumerous CPT and U-codes (e.g., 0473U, 0476U, 0530U, 0538U) specify NGS for large gene panels, cfDNA, and comprehensive tumor profiling
Authorization implicationNGS-based tests typically require prior authorization and detailed panel composition documentation per code-specific requirements
This part of the document enumerates modality-specific codes subject to prior authorization
Scope — modality-specific PAThis document enumerates modality-specific codes (CT, MRI, MRA, CTA, MEG) that are subject to prior authorization; clinical indications are referenced but not detailed in these chunks
Effective date for PA changesMany entries note effective 01/01/2025 for addition of site-of-care to medical necessity evaluation
Primary PA vendorCarelon is listed repeatedly as the prior authorization reviewer/manager for many modality and molecular test codes
Multiple new molecular genetic and proprietary U/J codes (including oncology, obstetrics, transplant, and broad genomic panels) were added with Carelon identified as the prior authorization administrator and effective add-dates of 07/01/2025 for many entries.
2026-01-01vendor_assignment_updateLatest
Selected molecular genetic U‑codes and certain medical transportation codes were reassigned to category 'Medical Transportation' with services management changed to Alacura/Carelon and additional effective add-dates (some added for 01/01/2026).